Interactions Between HIV and SIV with DC-SIGN & DC-SIGNR
HIV 和 SIV 与 DC-SIGN 之间的相互作用
基本信息
- 批准号:6646430
- 负责人:
- 金额:$ 39.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2006-05-31
- 项目状态:已结题
- 来源:
- 关键词:CD4 molecule HIV envelope protein cell line dendritic cells genetic strain human immunodeficiency virus 1 human subject immunologic substance development /preparation laboratory rabbit membrane proteins monoclonal antibody protein structure function receptor binding simian immunodeficiency virus virus infection mechanism virus receptors virus virus interaction
项目摘要
DESCRIPTION:(provided by applicant)The entry of HIV-1 into cells requires
interactions between the viral Env protein, CD4 and a coreceptor. While binding
to CD4 is required for efficient virus infection, attachment of virus to the
cell surface can be mediated by interactions with a variety of molecules, only
some of which have been well characterized. Attachment to the cell surface per
se can be a limiting step in the entry pathway. In vitro, infection of cell
lines and PBMC by HIV-1 can be enhanced by inclusion of polycations in the
virus inoculum or by centrifuging virus onto the cell surface. Infection of
activated T-cells can also be enhanced by first binding HIV-1 to dendritic cells (DCs). After removing unbound virus, addition of activated T cells
results in very efficient transmission of virus to these cellular targets.
Recently, a type lI integral membrane protein termed DC-SIGN has been shown to
mediate binding of HIV-1 to DCs. DC-SIGN contains a C-type (i.e.
calcium-dependent) lectin domain that mediates this process. Because DCs
migrate from peripheral mucosal tissues to lymph nodes, it has been proposed
that HIV uses DCs as carriers, allowing the virus to access lymphoid tissue.
More generally, the discovery of DC-SIGN raises the possibility that other
highly specific virus attachment factors exist. Indeed, we have found that
DC-SIGNR, which shares 77 percent amino acid identity with DC-SIGN, also
supports HIV binding and transmission. DC-SIGNR is expressed on endothelial
cells in lymph nodes, liver, and the placenta, while DC-SIGN is expressed on
DCs and some types of macrophages in vivo. The ability of DC-SIGN and DC-SIGNR
to bind virus with high affinity, to augment lymphocyte infection, and their
expression on cells in mucosal surfaces and the placenta where transmission
occurs leads us to hypothesize that these proteins facilitate viral binding to
cells, and that once bound, virions are modified and/or protected, and
ultimately presented more efficiently to key target cells that initiate viral
propagation and dissemination in the host. In this proposal, we will pursue
four Specific Aims that will explore the structure, function, and expression
patterns of DC- SIGN and DC-SIGNR. Furthermore, we will develop reagents that
will enable us to test the role of DC-SIGN in sexual transmission of virus
using the rhesus macaque model. We propose to take a highly collaborative
approach employing the skills and expertise of the Doms and Hoxie labs, as well
as collaborations with other laboratories so that these questions can be
addressed quickly and efficiently through the pursuit of 4 Specific Aims.
描述:(申请人提供)HIV-1进入细胞需要
病毒包膜蛋白、CD4和辅助受体之间的相互作用。边装订边
是有效感染病毒所必需的,将病毒附着到
细胞表面可以通过与各种分子的相互作用来调节,只有
其中一些已经被很好地描述了。附着在细胞表面上
Se可能是进入途径中的一个限制性步骤。在体外,细胞感染
HIV-1诱导的LINE和PBMC可通过在
病毒接种或通过将病毒离心到细胞表面。感染性疾病
激活的T细胞也可以通过首先将HIV-1与树突状细胞(DC)结合来增强。去除未结合的病毒后,添加激活的T细胞
导致病毒非常有效地传播到这些细胞靶点。
最近,一种被称为DC-SIGN的LI型整合膜蛋白被证明是
介导HIV-1与DC的结合。DC-SIGN包含C型(即
钙依赖的)凝集素结构域,介导这一过程。因为DC
从外周粘膜组织转移到淋巴结,已经被提出
HIV使用DC作为携带者,使病毒能够进入淋巴组织。
更广泛地说,DC-SIGN的发现增加了其他
存在高度特异的病毒附着因素。事实上,我们已经发现
DC-SIGNR与DC-SIGN的氨基酸同源性为77%,也
支持HIV绑定和传播。DC-SIGNR在内皮细胞上的表达
淋巴结、肝脏和胎盘中的细胞,而DC-SIGN在
DC和体内某些类型的巨噬细胞。DC-SIGN和DC-SIGNR的能力
以高亲和力结合病毒,增强淋巴细胞感染,以及它们的
细胞在粘膜表面和胎盘中的表达
发生导致我们假设这些蛋白质促进病毒结合到
细胞,一旦结合,病毒粒子被修饰和/或保护,以及
最终更有效地呈现给启动病毒的关键靶细胞
在宿主中的传播和传播。在这项提案中,我们将继续
四个具体的目标,将探索结构,功能和表达
DC-SIGN和DC-SIGNR的模式。此外,我们将开发出
将使我们能够测试DC-SIGN在性传播病毒中的作用
使用恒河猴模型。我们建议采取高度协作的
利用DOMS和Hoxie实验室的技能和专业知识的方法
作为与其他实验室的合作,所以这些问题可以
通过追求4个具体目标,快速有效地解决问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert W. Doms其他文献
HIV entry: are all receptors created equal?
HIV 进入:所有受体都是平等产生的吗?
- DOI:
10.1038/ni819 - 发表时间:
2002-07-01 - 期刊:
- 影响因子:27.600
- 作者:
Mark A. Goldsmith;Robert W. Doms - 通讯作者:
Robert W. Doms
Regulation of protein export from the endoplasmic reticulum.
内质网蛋白质输出的调节。
- DOI:
- 发表时间:
1988 - 期刊:
- 影响因子:0
- 作者:
J. Rose;Robert W. Doms - 通讯作者:
Robert W. Doms
Alzheimer's Aβ(1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells
阿尔茨海默病 Aβ(1–42) 在 NT2N 细胞的内质网/中间区室中生成。
- DOI:
10.1038/nm0997-1021 - 发表时间:
1997-09-01 - 期刊:
- 影响因子:50.000
- 作者:
David G. Cook;Mark S. Forman;Jane C. Sung;Susan Leight;Dennis L. Kolson;Takeshi Iwatsubo;Virgina M.-Y. Lee;Robert W. Doms - 通讯作者:
Robert W. Doms
Chemokines and coreceptors in HIV/SIV-host interactions.
HIV/SIV-宿主相互作用中的趋化因子和辅助受体。
- DOI:
- 发表时间:
1998 - 期刊:
- 影响因子:0
- 作者:
T. L. Hoffman;Robert W. Doms - 通讯作者:
Robert W. Doms
Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus–Type 1 Infection: Presented in part at the American Society of Hematology Meeting, San Diego, CA, 1997 and published in abstract form in Blood<em>90:2144, 1997 (abstr, suppl 1).</em>
- DOI:
10.1182/blood.v93.4.1145 - 发表时间:
1999-02-15 - 期刊:
- 影响因子:
- 作者:
Benhur Lee;Janina Ratajczak;Robert W. Doms;Alan M. Gewirtz;Mariusz Z. Ratajczak - 通讯作者:
Mariusz Z. Ratajczak
Robert W. Doms的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert W. Doms', 18)}}的其他基金
Interactions of Emerging Bunyaviruses with Host Cells
新兴布尼亚病毒与宿主细胞的相互作用
- 批准号:
8233375 - 财政年份:2011
- 资助金额:
$ 39.63万 - 项目类别:
Interactions of Emerging Bunyaviruses with Host Cells
新兴布尼亚病毒与宿主细胞的相互作用
- 批准号:
7670061 - 财政年份:2009
- 资助金额:
$ 39.63万 - 项目类别:
Finger Nucleases to Specifically Disrupt Coreceptor Expression
特异性破坏辅助受体表达的指状核酸酶
- 批准号:
7668215 - 财政年份:2009
- 资助金额:
$ 39.63万 - 项目类别:
Crimean congo hemorrhagic fever virus glycoproteins
克里米亚刚果出血热病毒糖蛋白
- 批准号:
6856987 - 财政年份:2005
- 资助金额:
$ 39.63万 - 项目类别:
Crimean congo hemorrhagic fever virus glycoproteins
克里米亚刚果出血热病毒糖蛋白
- 批准号:
7028300 - 财政年份:2005
- 资助金额:
$ 39.63万 - 项目类别:
相似海外基金
PROTEIN X-RAY CRYSTALLOGRAPHY: HIV ENVELOPE PROTEIN
蛋白质 X 射线晶体学:HIV 包膜蛋白
- 批准号:
7369566 - 财政年份:2005
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
6188002 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
6540025 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
2907163 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
6612844 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
6211668 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
6559805 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN
GP120 和 HIV 包膜蛋白促进疼痛
- 批准号:
6394025 - 财政年份:1999
- 资助金额:
$ 39.63万 - 项目类别:
Influence of HIV envelope protein oligomerization on interactions with chemokine receptors.
HIV 包膜蛋白寡聚化对与趋化因子受体相互作用的影响。
- 批准号:
nhmrc : 987004 - 财政年份:1998
- 资助金额:
$ 39.63万 - 项目类别:
CARG - People
Antiviral agents that disrupt the HIV envelope protein function
破坏 HIV 包膜蛋白功能的抗病毒药物
- 批准号:
nhmrc : 956047 - 财政年份:1995
- 资助金额:
$ 39.63万 - 项目类别:
CARG - Research